Sfoglia per Autore
P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance
2008 Torsello, A.; Garufi, C.; Cosimelli, M.; Diodoro, M. G.; Zeuli, M.; Vanni, B.; Campanella, C.; D'Angelo, C.; Sperduti, I.; Donnorso, R. P.; Cognetti, F.; Terzoli, E.; Mottolese, M.
Taxanes as primary chemotherapy for early breast cancer. Meta-analysis of randomized trials
2008 Cuppone, F.; Bria, E.; Carlini, P.; Milella, M.; Felici, A.; Sperduti, I.; Nistico, C.; Terzoli, E.; Cognetti, F.; Giannarelli, D.
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers
2009 Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F.
Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers
2009 Caruso, A.; Vigna, C.; Marozzo, B.; Sega, F. M.; Sperduti, I.; Cognetti, F.; Savarese, A.
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer. Preliminary results of a feasibility-phase II study aimed at cardiotoxicity
2009 Nistico, C.; Bria, E.; Vaccaro, V.; Cuppone, F.; Fornier, M.; Sperduti, I.; Carpino, A.; Lzzo, F.; Tropea, F.; Cognetti, F.; Terzoli, E.
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials
2009 Bria, E.; Cuppone, Francesca; Giannarelli, D.; Milella, M.; Ruggeri, E. M.; Sperduti, I.; Pinnaro, P.; Terzoli, E.; Cognetti, F.; Carlini, P.
Treatment of recurrent malignant gliomas with fotemustine monotherapy: Impact of dose and correlation with MGMT promoter methylation
2009 Fabi, A.; Metro, G.; Russillo, M.; Vidiri, A.; Carapella, M. C.; Maschio, M.; Cognetti, F.; Jandolo, B.; Mirri, M.; Sperduti, I.; Telera, S.; Carosi, M.; Pace, A.
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer
2009 Bria, E.; Milella, M.; Sperduti, I.; Alessandrini, G.; Visca, P.; Corzani, F.; Giannarelli, D.; Cerasoli, Virna; Cuppone, F.; Cecere, F. L.; Marchetti, A.; Sacco, R.; Mucilli, F.; Malatesta, S.; Guetti, Leonardo; Vitale, L.; Ceribelli, A.; Rinaldi, M.; Terzoli, E.; Cognetti, F.; Facciolo, F.
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
2010 Fabi, A.; Metro, G.; Di Benedetto, A.; Nistico, C.; Vici, P.; Melucci, E.; Antoniani, B.; Perracchio, L.; Sperduti, I.; Milella, M.; Cognetti, F.; Mottolese, M.
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
2010 Campanella, C.; Mottolese, Marcella.; Cianciulli, A.; Torsello, A.; Merola, R.; Sperduti, I.; Melucci, E.; Conti, S.; Diodoro, M. G.; Zeuli, M.; Paoletti, G.; Cognetti, F.; Garufi, C.
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials
2010 Cuppone, F.; Bria, E.; Giannarelli, D.; Vaccaro, V.; Milella, M.; Nistico, C.; Ruggeri, E. M.; Sperduti, I.; Bracarda, S.; Pinnaro, P.; Lanzetta, G.; Muti, P.; Cognetti, F.; Carlini, P.
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer
2010 Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F.
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials
2010 Loupakis, F.; Bria, E.; Vaccaro, V.; Cuppone, F.; Milella, M.; Carlini, P.; Cremolini, C.; Salvatore, L.; Falcone, A.; Muti, P.; Sperduti, I.; Giannarelli, D.; Cognetti, F.
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
2010 Garufi, C.; Torsello, A.; Tumolo, S.; Ettorre, G. M.; Zeuli, M.; Campanella, C.; Vennarecci, G.; Mottolese, Marcella; Sperduti, I.; Cognetti, F.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
2011 Fabi, A.; Di Benedetto, A.; Metro, G.; Perracchio, L.; Nistico, C.; Di Filippo, F.; Ercolani, C.; Ferretti, G.; Melucci, E.; Buglioni, S.; Sperduti, I.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella
Brain metastases from solid tumors. Disease outcome according to type of treatment and therapeutic resources of the treating center
2011 Fabi, A.; Felici, A.; Metro, G.; Mirri, A.; Bria, E.; Telera, S.; Moscetti, L.; Russillo, Michelangelo; Lanzetta, G.; Mansueto, G.; Pace, A.; Maschio, M.; Vidiri, A.; Sperduti, I.; Cognetti, F.; Carapella, CARMINE MARIA
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis
2011 Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D.
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials
2011 Cuppone, F.; Bria, E.; Vaccaro, V.; Puglisi, F.; Fabi, A.; Sperduti, I.; Carlini, P.; Milella, M.; Nistico, C.; Russillo, M.; Papaldo, P.; Ferretti, G.; Aapro, M.; Giannarelli, D.; Cognetti, F.
The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability.
2012 Koudriavtseva, T; Onesti, Emanuela; Pestalozza, If; Sperduti, Isabella; Jandolo, B.
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy
2012 Milella, M.; Nuzzo, C.; Bria, E.; Sperduti, I.; Visca, P.; Buttitta, F.; Antoniani, B.; Merola, R.; Gelibter, A.; Cuppone, F.; D'Alicandro, V.; Ceribelli, A.; Rinaldi, M.; Cianciulli, A.; Felicioni, L.; Malatesta, S.; Marchetti, A.; Mottolese, Marcella.; Cognetti, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance | 2008 | Torsello, A.; Garufi, C.; Cosimelli, M.; Diodoro, M. G.; Zeuli, M.; Vanni, B.; Campanella, C.; D'Angelo, C.; Sperduti, I.; Donnorso, R. P.; Cognetti, F.; Terzoli, E.; Mottolese, M. | |
| Taxanes as primary chemotherapy for early breast cancer. Meta-analysis of randomized trials | 2008 | Cuppone, F.; Bria, E.; Carlini, P.; Milella, M.; Felici, A.; Sperduti, I.; Nistico, C.; Terzoli, E.; Cognetti, F.; Giannarelli, D. | |
| Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers | 2009 | Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F. | |
| Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers | 2009 | Caruso, A.; Vigna, C.; Marozzo, B.; Sega, F. M.; Sperduti, I.; Cognetti, F.; Savarese, A. | |
| Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer. Preliminary results of a feasibility-phase II study aimed at cardiotoxicity | 2009 | Nistico, C.; Bria, E.; Vaccaro, V.; Cuppone, F.; Fornier, M.; Sperduti, I.; Carpino, A.; Lzzo, F.; Tropea, F.; Cognetti, F.; Terzoli, E. | |
| Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials | 2009 | Bria, E.; Cuppone, Francesca; Giannarelli, D.; Milella, M.; Ruggeri, E. M.; Sperduti, I.; Pinnaro, P.; Terzoli, E.; Cognetti, F.; Carlini, P. | |
| Treatment of recurrent malignant gliomas with fotemustine monotherapy: Impact of dose and correlation with MGMT promoter methylation | 2009 | Fabi, A.; Metro, G.; Russillo, M.; Vidiri, A.; Carapella, M. C.; Maschio, M.; Cognetti, F.; Jandolo, B.; Mirri, M.; Sperduti, I.; Telera, S.; Carosi, M.; Pace, A. | |
| A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer | 2009 | Bria, E.; Milella, M.; Sperduti, I.; Alessandrini, G.; Visca, P.; Corzani, F.; Giannarelli, D.; Cerasoli, Virna; Cuppone, F.; Cecere, F. L.; Marchetti, A.; Sacco, R.; Mucilli, F.; Malatesta, S.; Guetti, Leonardo; Vitale, L.; Ceribelli, A.; Rinaldi, M.; Terzoli, E.; Cognetti, F.; Facciolo, F. | |
| Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies | 2010 | Fabi, A.; Metro, G.; Di Benedetto, A.; Nistico, C.; Vici, P.; Melucci, E.; Antoniani, B.; Perracchio, L.; Sperduti, I.; Milella, M.; Cognetti, F.; Mottolese, M. | |
| Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab | 2010 | Campanella, C.; Mottolese, Marcella.; Cianciulli, A.; Torsello, A.; Merola, R.; Sperduti, I.; Melucci, E.; Conti, S.; Diodoro, M. G.; Zeuli, M.; Paoletti, G.; Cognetti, F.; Garufi, C. | |
| Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials | 2010 | Cuppone, F.; Bria, E.; Giannarelli, D.; Vaccaro, V.; Milella, M.; Nistico, C.; Ruggeri, E. M.; Sperduti, I.; Bracarda, S.; Pinnaro, P.; Lanzetta, G.; Muti, P.; Cognetti, F.; Carlini, P. | |
| Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer | 2010 | Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F. | |
| Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials | 2010 | Loupakis, F.; Bria, E.; Vaccaro, V.; Cuppone, F.; Milella, M.; Carlini, P.; Cremolini, C.; Salvatore, L.; Falcone, A.; Muti, P.; Sperduti, I.; Giannarelli, D.; Cognetti, F. | |
| Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial | 2010 | Garufi, C.; Torsello, A.; Tumolo, S.; Ettorre, G. M.; Zeuli, M.; Campanella, C.; Vennarecci, G.; Mottolese, Marcella; Sperduti, I.; Cognetti, F. | |
| HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care | 2011 | Fabi, A.; Di Benedetto, A.; Metro, G.; Perracchio, L.; Nistico, C.; Di Filippo, F.; Ercolani, C.; Ferretti, G.; Melucci, E.; Buglioni, S.; Sperduti, I.; Papaldo, P.; Cognetti, F.; Mottolese, Marcella | |
| Brain metastases from solid tumors. Disease outcome according to type of treatment and therapeutic resources of the treating center | 2011 | Fabi, A.; Felici, A.; Metro, G.; Mirri, A.; Bria, E.; Telera, S.; Moscetti, L.; Russillo, Michelangelo; Lanzetta, G.; Mansueto, G.; Pace, A.; Maschio, M.; Vidiri, A.; Sperduti, I.; Cognetti, F.; Carapella, CARMINE MARIA | |
| Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis | 2011 | Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D. | |
| Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials | 2011 | Cuppone, F.; Bria, E.; Vaccaro, V.; Puglisi, F.; Fabi, A.; Sperduti, I.; Carlini, P.; Milella, M.; Nistico, C.; Russillo, M.; Papaldo, P.; Ferretti, G.; Aapro, M.; Giannarelli, D.; Cognetti, F. | |
| The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. | 2012 | Koudriavtseva, T; Onesti, Emanuela; Pestalozza, If; Sperduti, Isabella; Jandolo, B. | |
| EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy | 2012 | Milella, M.; Nuzzo, C.; Bria, E.; Sperduti, I.; Visca, P.; Buttitta, F.; Antoniani, B.; Merola, R.; Gelibter, A.; Cuppone, F.; D'Alicandro, V.; Ceribelli, A.; Rinaldi, M.; Cianciulli, A.; Felicioni, L.; Malatesta, S.; Marchetti, A.; Mottolese, Marcella.; Cognetti, F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile